Medtech startup Avisi Technologies has raised a seed round, CEO Rui Jing Jiang confirmed to Technical.ly. The company — a 2020 RealLIST Startups honoree — aims to treat open-angle glaucoma with an ocular implant that’s designed to remove excess fluid from inside the eye. Its recent funding injection totals just over $4 million.
The raise will expedite the company’s clinical development of its VisiPlate product and go toward additional research and development, Jiang said. Avisi will also be transitioning its HQ from Philly to the Bay Area, though the team will continue to work with the Singh Center for Nanotechnology at the University of Pennsylvania.
Joining the board of directors is Dr. Catherine Mohr of Good Growth Capital and the Intuitive Surgical Foundation, and Paul Norris, partner at Accanto.
READ FULL ARTICLE HERE
